Business Description
Rhythm Biosciences Ltd
ISIN : AU000000RHY2
Share Class Description:
FRA:0RY: Ordinary SharesDescription
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 32.39 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15.6 | |||||
3-Year EPS without NRI Growth Rate | -2.9 | |||||
3-Year FCF Growth Rate | -10.1 | |||||
3-Year Book Growth Rate | 17.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.16 | |||||
9-Day RSI | 39.47 | |||||
14-Day RSI | 39.21 | |||||
6-1 Month Momentum % | -36.65 | |||||
12-1 Month Momentum % | -86.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.05 | |||||
Quick Ratio | 2.04 | |||||
Cash Ratio | 1.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -4.54 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -162.71 | |||||
ROA % | -131.53 | |||||
ROIC % | -657.54 | |||||
ROC (Joel Greenblatt) % | -1290.79 | |||||
ROCE % | -145.44 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 10.33 | |||||
EV-to-EBIT | -1.82 | |||||
EV-to-EBITDA | -1.87 | |||||
EV-to-FCF | -1.7 | |||||
Price-to-Net-Current-Asset-Value | 3.65 | |||||
Price-to-Net-Cash | 3.65 | |||||
Earnings Yield (Greenblatt) % | -54.95 | |||||
FCF Yield % | -54.06 |